Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

IO

Roche Basel Switzerland

Roche’s Tecentriq yields positive data in early stage NSCLC

PD-L1 inhibitor improved disease-free survival in phase 3 IMpower010 study

- PMLiVE

FDA advisory committee to review oncology accelerated approvals

Review comes after voluntary indication withdrawals for a number of cancer therapies

- PMLiVE

Novartis’ canakinumab misses the mark in previously treated NSCLC

Drug failed to improve survival in previously-treated metastatic NSCLC patients

- PMLiVE

Pfizer’s ALK inhibitor Lorbrena scores expanded FDA approval for first-line NSCLC

The European Medicines Agency is also reviewing an application for the drug

- PMLiVE

Sanofi, Regeneron’s Libtayo scores first-line NSCLC approval in the US

New approval will see Libtayo compete with blockbuster immunotherapy Keytruda

- PMLiVE

AZ withdraws Imfinzi in the US for advanced bladder cancer after post-marketing study fail

Immunotherapy failed to hit primary endpoint in phase 3 DANUBE trial last year

- PMLiVE

New dosing option for AZ’s Imfinzi approved in the EU and UK

Additional option extends dosing from two weeks to four weeks

- PMLiVE

BMS’ Opdivo is first immunotherapy to score phase 3 win in pre-surgery NSCLC

Checkpoint inhibitor plus chemo meets first primary endpoint in late-stage trial

- PMLiVE

Keytruda doubles five-year survival rate in NSCLC

Merck reveals long-term efficacy data for blockbuster immunotherapy

- PMLiVE

Janssen’s EGFR-targeting treatment regimen shows early benefit in lung cancer

Positive interim results presented at 2020 ESMO virtual congress

AstraZeneca AZ

AZ’s Tagrisso cuts risk of EGFR-positive NSCLC spreading to the brain

Results showing EGFR-inhibitor improves outcomes in adjuvant setting released at ESMO 2020 virtual congress

AstraZeneca AZ

AZ scores FDA priority review for new Imfinzi fixed-dose regimen

Four-week dosing schedule offers new flexibility for patients

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links